p53 tumor supresor gene in digestive cancer;Gen supresor de tumores p53 en neoplasias digestivas

Revista Medica de Chile

Volumn 128, Issue 11, 2000, Pages 1269-1278

  Roa S, Juan C ^a   Roa E, Iván ^b   Araya O, Juan C ^b   Villaseca H, Miguel A ^b   Melo A, Angélica ^b   Burgos S, Luis ^b  

^a UNIVERSIDAD DE LA FRONTERA   (Chile)

^b NONE

Author keywords

Digestive system neoplasm; Genes, p53; Genetic markers; Genetic predisposition to disease

Indexed keywords

DIGESTIVE SYSTEM TUMOR; GENETIC MARKER; GENETICS; HUMAN; IMMUNOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

DIGESTIVE SYSTEM NEOPLASMS; GENES, P53; GENETIC MARKERS; HUMANS; PROGNOSIS;

EID: 0034332510     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. MEDINA E, CSENDES A. Características epidemiológicas del cáncer en Chile. Rev Méd Chile 1983; 111: 69-75.
2. MEDINA E. Las enfermedades digestivas en Chile: Panorama epidemiológico. Rev Méd Chile 1988; 116: 282-8.
3. LEVINE AJ. p53 the cellular gatekeeper for growth and division. Cell 1997; 7; 88: 323-31.
4. VOGELSTEIN B, KINZLER KW. p53 function and dysfunction. Cell 1992; A21; 70: 523-6.
5. VOGELSTEIN B, KINZLER K. Colorectal tumors. En Vogelstein B, Kinzler K, eds. The genetic basis of human cancer. New York Ed McGraw Hill 1998; 565-87.
6. HOLLSTEIN M, SIDRANSKY D, VOGELSTEIN B, HARRIS CC. p53 mutations in human cancers. Science 1991; 5; 253: 49-53.
7. WYNFORD-THOMAS D. P53 in tumour pathology: Can we trust immunocytochemistry? J Pathol 1992; 166: 329-30.
8. ROA I, ROA JC, MELO A, ARAYA JC, VILLASECA M, ARETXABALA X. Mutación del gen p53 en el cáncer de la vesícula biliar. Rev Méd Chile 2000; 128: 251-8.
9. KANAMOTO A, KATO H, TACHIMORI Y, WATANABE H, NAKANISUI Y, KONDO H, YAMAGUCHI H, GOTODA T, MURO K, MATSUMURA Y. No prognostic significance of p53 expression in esophageal squamous cellcarcinoma. J Surg Oncol 1999; 72: 94-8.
10. SARBIA M, PORSCHEN R, BORCHAHD F, HORSTMANN O, WILLERS R, GABBERT HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994; 74: 2218-23.
11. SUWIWAT S, ODA H, SHIMIZU Y, ISHIKAWA T. Prevalence of p53 mutations and protein expression in esophageal cancers in southern Thailand. Int J Cancer 1997; 72: 23-6.
12. COGGI G, BOSARI S, RONCALLI M, GRAZIANI D, BOSSI P, VIALE G, ET AL. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997; 79: 425-32.
13. KOBAYASHI S, KOIDE Y, ENDO M, ISONO K, OCHIAI T. The p53 gene mutation is of prognostic value in esophageal squamous cellcarcinoma patients in unified stages of curability. Am J Surg 1999; 177: 497-502.
14. BENNETT WP, HOLLSTEIN MC, METCALF RA, WELSH JA, HE A, ZHU SM, ET AL. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992; 52: 6092-7.
15. SHI ST, YANG GY, WANG LD, XUE Z, FENG B, DING W, XING EP, YANG CS. Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions. Carcinogenesis 1999; 20: 591-7.
16. IRELAND AP, SHIBATA DK, CHANDRASOMA P, LORD RV, PETERS JH, DEMEESTER TR. Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg 2000; 231: 179-87.
17. UCHINO S, SAITO T, INOMATA M, OSAWA N, CHIKUBA K, ETOH K, KOBAYASHI M. Prognostic significance of the p53 mutation in esophageal cancer. Jpn J Clin Oncol 1996; 26: 287-92.
18. MONGES GM, SEITZ JF, GIOVANNINI MF, GOUVERNET JM, TORRENTE MA, HASSOUN JA. Prognostic value of p53 protein expression in squamous cell carcinoma of the esophagus. Cancer Detect Prev 1996; 20: 63-7.
19. GIMÉNEZ A, DE HARO LM, PARRILLA P, BERMEJO J, PÉREZ-GUILLERMO M, ORTIZ MA. Immunohistochemical detection of p53 protein could improve the management of some patients with Barrett esophagus and mild histologicalterations. Arch Pathol Lab Med 1999; 123: 1260-3.
20. KLUMP B, HSIEH CJ, HOLZMANN K, BORCHARD F, GACO V, GRESCHNIOK A, ECKARDT VF, BETTENDORF U, GREGOR M, FORSCHEN R. Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's esophagus -a iongitudinal study. Z Gastroenterol 1999; 37: 1005-11.
21. TAHARA E. Molecular biology of gastric cancer. World J Surg 1995; 19: 484-8; ver discusión en pags 489-90.
22. POWELL S. Stomach cancer in Vogelstein B, Kinzler K, eds. The genetic basis of human cancer. New York Ed McGraw Hill 1998; 647-52.
23. ARANDA M, NÁQUIRA N, KARQUE R, MENDOZA H, SEPÚLVEDA C, SILVA C. Mutations of the p53 suppressor gene in gastric adenocarcinoma. Rev Méd Chile 1998; 126: 525-32.
24. OCHIAI A, YAMAUCHI Y, HIROHASHI S. p53 mutations in the nonneoplastic mucosa of the human stomach showing intestinal metaplasia. Int J Cancer 1996; 69: 28-33.
25. ICHIYOSHI Y, OIWA H, TOMISAKI S, SAKAGUCHI Y, OHNO S, MAEHARA Y, SUGIMACHI K. Overexpression of p53 is associated with growth pattern and prognosis in advanced gastric cancer. Hepatogastroenterology 1997; 44: 546-53.
26. MONIG SP, EIDT S, ZIRBES TK, STIPPEL D, BALDUS SE, PICHLMAIER H. p53 expression in gastric cancer: clinicopathological correlation and prognostic significance. Dig Dis Sci 1997; 42: 2463-7.
27. IKEGUCHI M, SAITO H, KONDO A, TSUJITANI S, MAETA M, KAIBARA N. Mutated p53 protein expression and proliferative activity in advanced gastric cancer. Hepatogastroenterology 1999; 46: 2648-53.
28. KATAOKA M, OKABAYASHI T, JOHIRA H, NAKATANI S, NAKASHIMA A, TAKEDA, ET AL. Aberration of p53 and DCC in gastric and colorectal cancer. Oncol Rep 2000; 7: 99-103.
29. XIANGMING C, HOKITA S, NATSUGOE S, TANABE G, BABA M, TAKAO S, ET AL. Cooccurrence of reduced expression of alpha-catenin and overexpression of p53 isa predictor of lymph node metastasis in early gastric cancer. Oncology 1999; 57: 131-7.
30. VILLASECA MA, ROA I, ARAYA JC, ROA JC, FLORES P. Double immunostaining for p53 and molecular chaperone hsp72/73 in gastriccarcinoma. Mol Pathol 1997; 50: 317-21.
31. VILLASECA M, ARAYA JC, ROA I, ROA JC. Cáncer ǵstrico y regulación del crecimiento tumoral. Estudio de marcadores de proliferación celular y del complejo proteínas p53/p21WAF1/CIP1/mdm-21. Rev Méd Chile 2000; 128: 127-36.
32. MARTIN HM, FILIPE MI, MORRIS RW, LANE DP, SILVESTRE F. p53 expression and prognosis in gastric carcinoma. Int J Cancer 1992; 1; 50: 859-62.
33. LEE WJ, SHUN CT, HONG RL, WU MS, CHANG KJ, CHEN KM. Overexpression of p53 predicts shorter survival in diffuse type gastric cancer. Br J Surg 1998; 85: 1138-42.
34. CHO JH, ROE IH, JIN YJ. Diagnostic p53 expression in gastric endoscopic mucosal resection. J Korean Med Sci 1999; 14: 412-6.
35. JEN J, POWELL SM, PAPADOPOULOS N, SMITH KJ, HAMILTON SR, VOGELSTEIN B, KINZLER KW. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 1; 54: 5523-6.
36. SHIRASAWA S, FURUSE M, YOKOYAMA N, SASAZUKI T. Altered growth of human colon cancer cell lines disrupted at activated Kiras. Science 1993; 260: 85-8.
37. LIM BH, SOONG R, GRIEU F, ROBBINS PD, HOUSE AK, IACOPETTA BJ. p53 accumulation and mutation are prognostic indicators of poor survival in human gastric carcinoma. Int J Cancer 1996; 21; 69: 2004.
38. TAMURA G, KIHANA T, NOMURA K, TERADA M, SUGIMURA T, HIROHASHI S. Detection of frequent p53 gene mutations in primary gastric cancer by cell-sorting and polymerase chain reaction singlestrand conformation polymorphismanalysis. Cancer Res 1991; 1; 51: 3056-8.
39. SUGIMURA T, FUJIMURA S, BABA T. Tumor production in the glandular stomach and alimentary tract of the rat byN-methyl-N′nitro-N-nitrosoguanidine. Cancer Res 1970; 30: 455-65.
40. YAMABA Y, YOSHIDA T, HAYASHI K, SEKIYA T, YOKOTA J, HIROHASHI S, NAKATANI K, NAKANO H, SUGIMURA T, TERADA M. p53 gene mutations in gastric cancer metastases and in gastric cancer cell lines derived from metastases. Cancer Res 1991; 51: 5800-5.
41. KUWABARA S, AJIOKA Y, WATANABE H, HITOMI J, NISHIKURA K, HATAKEYAMA K. Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma. Jpn J Cancer Res 1998; 89: 405-10.
42. SERUCA R, DAVID L, CASTEDO S, VEIGA I, BORRESEN AL, SOBRINHO SIMOES M. p53 alterations in gastric carcinoma: a study of 56 primary tumors and 204 nodal metastases. Cancer Genet Cytogenet 1994; 75: 45-50.
43. MIRVISH SS. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett 1995; 93: 17-48.
44. POREMBA C, YANDELL DW, HUANG Q, LITTLE JB, MELLIN W, SCHMID KW, ET AL. Frequency and spectrum of p53 mutations in gastric cancer -a molecular genetic and immunohistochemical study. Virchows Arch 1995; 426: 447-55.
45. POWELL S. Stomach Cancer. In: Vogelstein B, Kinzler K, eds. The Genetic Basis of Human Cancer. New York: McGraw-Hill 1998; 647-52.
46. MEDINA E. Enfermedades del Sistema Digestivo en Chile. Rev Méd Chile 1988; 116: 282-8.
47. ARAYA J, ROA I, ARETXABALA X, SALINAS C. Cáncer gástrico en la novena región de Chile. Análisis de 233 casos. Rev Méd Chile 1989; 117: 773-9.
48. CSENDES A, SMOK G, MEDINA E, SALGADO I, RIVERA R, QUITRAL M. Características del cuadro clínico del cáncer gástrico 1958-1990. Rev Méd Chile 1992; 120: 36-42.
49. TERRIS B, MUZEAU F, SAUVANET A, BELGHITI J, FLEJOU JF. Gene p53 mutations and overexpression of p53 protein in tumors of the Vater's ampulla. Gastroenterol Clin Biol 1998; 22: 495-9.
50. ZHAO B, KIMURA W, FUTAKAWA N, MUTO T, KUBOTA K, HARIHARA Y, TAKAYAMA T, MAKUUCHI M. p53 and p21/Waf1 protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater. Am J Gastroenterol 1999; 94: 2128-34.
51. PARK SH, KIM YI, PARK YH, KIM SW, KIM KW, KIM YT, KIM WH. Clinicopathologic correlation of p53 protein overexpression in adenoma andcarcinoma of the ampulla of Vater. World J Surg 2000; 24: 54-9.
52. WATANABE H, DATE K, ITOI T, MATSUBAYASHI H, YOKOYAMA N, YAMANO M, AJIOKA Y, NISHIKURA K. Histological and genetic changes in malignant transformation of gallbladder adenoma. Ann Oncol 1999; 10: 136-9.
53. ITOI T, WATANABE H, AJIOKA Y, OOHASHI Y, TAKEL K, NISHIKURA K, NAKAMURA Y, HORIL A, SAITO T. APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenomaof the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int 1996; 46: 333-40.
54. WISTUBA II, MIQUEL JF, GAZDAR AF, ALIBORES-SAAVEDRA J. Gallbladder adenomas have molecular abnormalities different from those presentin gallbladder carcinomas. Hum Pathol 1999; 30: 21-5.
55. ROA I, ARAYA JC, WISTUBA I, VILLASECA M, DE ARETXABALA X, BURGOS L. Cáncer de la vesícula biliar en la IX región de Chile. Impacto del estudio anatomopatológico de 474 casos. Rev Méd Chile 1994; 122: 1248-56.
56. HANADA K, ITOH M, FUJII K, TSUCHIDA A, OOISHI H, KAJIYAMA G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalousjunction of the pancreaticobiliary duct. Cancer 1996; 1; 77: 452-8.
57. WASHINGTON K, GOTFFRIED MR. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts. Liver 1996; 16: 99-104.
58. AJIKI T, ONOYAMA H, YAMAMOTO M, ASAKA K, FUJIMORI T, MAEDA S, SAITOH Y. p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 1996; 43: 521-6.
59. ITOI T, TAKEI K, SHINOHARA Y, TAKEDA K, NAKAMURA K, HORIBE T, ET AL. K-ras codon 12 and p53 mutations in biopsy specimens and bile from biliary tract cancers. Pathol Int 1999; 49: 30.
60. WISTUBA II, GAZDAR AF, ROA I, ALIBORES-SAAVEDRA J. p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study. Hum Pathol 1996; 27: 360-5.
61. ROA I, VILLASECA M, ARAYA J, ROA J, DE ARETXABALA X, MELO A, IBACACHE. G. p53 tumour suppressor gene protein expression in early and advanced gallbladder carcinoma. Histopathology 1997; 31: 226-30.
62. ROA I, VILLASECA M, ARAYA JC, ROA J, DE ARETXABALA X, FUENTEALBA P, MELO A. DNA ploidy pattern and tumor suppressor gene p53 expression in gallbladder carcinoma. Cancer Epidemiol Biomarkers Prev 1997; 6: 547-50.
63. ITOI T, WATANABE H, YOSHIDA M, AJIOKA Y, NISHIKURA K, SAITO T. Correlation of p53 protein expression with gene mutation in gallbladder carcinomas. Pathol Int 1997; 47: 525-30.
64. YOKOYAMA N, HITOMI J, WATANABE H, AJIOKA Y, PRUYAS M, SERRA I, SHIRAI Y, HATAKEYAMA K. Mutations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev 1998; 7: 297-301.
65. FUJII K, YOKOZAKI H, YASUI W, KUNIYASU H, HIRATA M, KAJIYAMA G, TAHARA E. High frequency of p53 gene mutation in adenocarcinomas of the gallbladder. Cancer Epidemiol Biomarkers Prev 1996; 5: 461-4.
66. TAKAGI S, NAITO E, YAMANOUCHI H, OHTSUKA H, KOMINAMI R, YAMAMOTO M. Mutation of the p53 gene in gallbladder cancer. Tohoku J Exp Med 1994; 172: 283-9.
67. HANADA K, ITOH M, FUJII K, TSUCHIDA A, HIRATA M, IWAO T, EGUCHI N, SASAKI T, MATSUBARA K, KAJIYAMA G. TP53 mutations in stage I gallbladder carcinoma with special attention to growthpatterns. Eur J Cancer 1997; 33: 1136-40.
68. WISTUBA II, ALBORES-SAAVEDRA J. Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. J Hepatobiliary Pancreat Surg 1999; 6: 237-44.
69. LEVIN B. Gallbladder carcinoma. Ann Oncol 1999; 10: 129-30.
70. WISTUBA I, SUGIO K, HUNG J, KISHIMOTO Y, VIRMANI A, ROA I, ET AL. Allele specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Research 1995; 55: 2511-5.
71. SMITH D, CHAN C, GOH H. A detailed study of p53 mutations in colorectal cancer in Singapore. Ann Acad Med Singapore 1994; 23: 803-9.
72. GOH H, CHAN C, KHINE K, SMITH D. p53 and behaviour of colorectal cancer. Lancet 1994; 344: 233-4.
73. CUNNINGHAM J, LUST J, SCHAID D, BREN G, CARPENTER H, RIZZA E, KOVACH J, THIBODEAU S. Expression of p53 and 17p Allelic Loss in Colorectal Carcinoma. Cancer Res 1992; 52: 1974-80.
74. ROA JC, VILLASECA MA, ROA I, ARAYA JC, OKAYASU I, FLORES P, FLORES M. Expresión Inmunohistoquímica de la oncoproteína p53 en adenomas y adenocarcinomas del intestino grueso. Rev Méd Chile 1997; 125: 523-29.
75. KRESSNER U, INGANAS M, BYDING S, BLIKSTAD I, PAHLMAN L, GLIMELIUS B, LINDMARK G. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999; 17: 593-9.
76. STARZYNSKA T, BROMLEY M, MARLICZ K, ROBERTS SA, UCINSKI M, STERN PL. Accumulation of p53 in relation to long-term prognosis in colorectal carcinoma. Eur J Gastroenterol Hepatol 1997; 9: 183-6.
77. HAMELIN R, LAURENT-PUIG P, OLSCHWANG S, JEGO N, ASSELAIN D, REMVIKOS Y, GIRODET J, SALMON RJ, THOMAS G. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994; 106: 42-8.
78. INIESTA P, VEGA FJ, CALDES T, MASSA M, DE JUAN C, CERDAN F, ET AL. p53 exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer. Cancer Lett 1998; 130: 153-60.
79. SCOTT N, SAGAR P, STEWART J, BLAIR G, DIXON M, QUIRKE P. P53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991; 63: 317-9.
80. WISTUBA I, CAPURRO I. Epidermoid carcinoma of the cervix uteri: molecular abnormalities of p53 and rbgenes. Rev Méd Chile 1996; 124: 553-60.
81. WERNESS BA, LEVINE AJ, HOWLEY PM. Association of human papilloma virus types 16 and 18 Ed proteins with p53. Science 1990; 6; 248: 76-9.
82. SCHEFFNER M, WERNESS BA, HUIBREGTSE JM, LEVINE AJ, HOWLEY PM. The Ed oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 21; 63: 1129-36.
83. MOSNIER JF, PERRET A, VINDIMIAN M, DUMOLLARD, BALIQUE JG, PERPOINT B, BOUCHERON S. An immunohistochemical study of the simultaneus expresssion of bc1-2 and p53 oncoproteins in epithelial turners of the colon and rectum. Arch Pathol Lab Med 1996; 120: 654-9.
84. DOWELL S, HALL P. The clinical relevance of the p53 tumour suppressor gene. Cytopathology 1994; 5: 133-45.